Shire PLC Stock Price, News & Analysis (NASDAQ:SHPG)

$147.37 2.74 (1.89 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$144.63
Today's Range$145.16 - $147.87
52-Week Range$137.17 - $192.15
Volume1.64 million shs
Average Volume1.15 million shs
Market Capitalization$43.61 billion
P/E Ratio9.58
Dividend Yield0.66%
Beta1.6

About Shire PLC (NASDAQ:SHPG)

Shire PLC logoShire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Sector: Pharmaceuticals - NEC
  • Symbol: NASDAQ:SHPG
  • CUSIP: N/A
  • Web: www.shire.com
Debt:
  • Debt-to-Equity Ratio: 0.55%
  • Current Ratio: 0.98%
  • Quick Ratio: 0.52%
Price-To-Earnings:
  • Trailing P/E Ratio: 9.58
  • Forward P/E Ratio: 9.82
  • P/E Growth: 0.77
Sales & Book Value:
  • Annual Sales: $11.3966 billion
  • Price / Sales: 3.88
  • Cash Flow: $17.34 per share
  • Price / Cash: 8.50
  • Book Value: $108.69 per share
  • Price / Book: 1.36
Dividend:
  • Annual Dividend: $0.92
  • Dividend Yield: 0.7%
Profitability:
  • Trailing EPS: $5.31
  • Net Income: $327.4 million
  • Net Margins: 10.95%
  • Return on Equity: 14.41%
  • Return on Assets: 6.60%
Misc:
  • Employees: 23,906
  • Outstanding Shares: 300,430,000
 
Frequently Asked Questions for Shire PLC (NASDAQ:SHPG)

What is Shire PLC's stock symbol?

Shire PLC trades on the NASDAQ under the ticker symbol "SHPG."

How often does Shire PLC pay dividends? What is the dividend yield for Shire PLC?

Shire PLC declared a semiannual dividend on Friday, August 11th. Shareholders of record on Friday, September 8th will be given a dividend of $0.1527 per share on Friday, October 20th. This represents a yield of 0.21%. The ex-dividend date is Thursday, September 7th. View Shire PLC's Dividend History.

How were Shire PLC's earnings last quarter?

Shire PLC (NASDAQ:SHPG) posted its earnings results on Friday, October, 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $3.64 by $0.17. The biopharmaceutical company had revenue of $3.70 billion for the quarter. Shire PLC had a return on equity of 14.41% and a net margin of 10.95%. Shire PLC's revenue for the quarter was up 7.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.17 EPS. View Shire PLC's Earnings History.

When will Shire PLC make its next earnings announcement?

Shire PLC is scheduled to release their next quarterly earnings announcement on Thursday, February, 15th 2018. View Earnings Estimates for Shire PLC.

What guidance has Shire PLC issued on next quarter's earnings?

Shire PLC issued an update on its FY17 earnings guidance on Friday, October, 27th. The company provided earnings per share (EPS) guidance of $14.80-15.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $14.92. The company issued revenue guidance of $14.9-15.3 billion, compared to the consensus revenue estimate of $14.97 billion.

Where is Shire PLC's stock going? Where will Shire PLC's stock price be in 2017?

15 analysts have issued 12-month price objectives for Shire PLC's stock. Their predictions range from $160.00 to $245.00. On average, they anticipate Shire PLC's stock price to reach $212.18 in the next year. View Analyst Ratings for Shire PLC.

What are Wall Street analysts saying about Shire PLC stock?

Here are some recent quotes from research analysts about Shire PLC stock:

  • 1. According to Zacks Investment Research, "The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio, acquiring roughly 23% of the total market by the end of Jun 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Moreover, shares have underperformed the industry so far this year. Estimates have risen ahead of Q3 earnings. The company has a mixed record of earnings surprises in recent quarters." (10/27/2017)
  • 2. Cantor Fitzgerald analysts commented, "This morning, SHPG announced that the Marketing Authorization Application (MAA) for Lifitegrast has been validated by the UK as the Reference Member State involved in the Decentralized Procedure (DCP)." (8/15/2017)
  • 3. Jefferies Group LLC analysts commented, "SHPG posted strong 4Q16 revs ($3.8B vs $3.7B JEF) and EPS ($3.37 vs $3.26 JEF) as nearly all core franchises performed well. In particular, GI and Orphan Diseases showed strength. As for legacy BXLT, Immunoglobulins and Hemophilia performed well while Inhibitors lagged. We like the setup for 2017. If mgt executes on core brands, the Xiidra launch, and the BXLT integration, we could envision share price outperformance, augmented by significant deleveraging." (2/17/2017)

Who are some of Shire PLC's key competitors?

Who are Shire PLC's key executives?

Shire PLC's management team includes the folowing people:

  • Flemming Ornskov M.D., Chief Executive Officer, Executive Director (Age 59)
  • Jeffrey Poulton, Chief Financial Officer, Executive Director (Age 49)
  • Joanne Cordeiro, Chief Human Resource Officer
  • Gisele Dion, Chief Accounting Officer, Corporate Controller (Age 51)
  • William Mordan, General Counsel, Company Secretary (Age 47)
  • Perry Sternberg, Head - U.S. Commercial (Age 48)
  • Kim Stratton, Head - International Commercial (Age 54)
  • Philip J. Vickers, Head - Research and Development (Age 56)
  • Matthew Walker, Head - Technical Operations (Age 53)
  • Susan Saltzbart Kilsby, Independent Non-Executive Chairman of the Board (Age 58)

Who owns Shire PLC stock?

Shire PLC's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Harding Loevner LP (42.47%), Janus Henderson Group PLC (0.58%), Ameriprise Financial Inc. (0.53%), Boston Partners (0.49%), Third Point LLC (0.40%) and Jennison Associates LLC (0.26%). View Institutional Ownership Trends for Shire PLC.

Who sold Shire PLC stock? Who is selling Shire PLC stock?

Shire PLC's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Allianz Asset Management GmbH, Sei Investments Co., Dividend Assets Capital LLC, Rockefeller Financial Services Inc., Third Avenue Management LLC, Zweig DiMenna Associates LLC and Point72 Asset Management L.P.. View Insider Buying and Selling for Shire PLC.

Who bought Shire PLC stock? Who is buying Shire PLC stock?

Shire PLC's stock was purchased by a variety of institutional investors in the last quarter, including Harding Loevner LP, Third Point LLC, Sterling Capital Management LLC, Janus Henderson Group PLC, Seatown Holdings Pte. Ltd., Van ECK Associates Corp, Boston Partners and GMT Capital Corp. View Insider Buying and Selling for Shire PLC.

How do I buy Shire PLC stock?

Shares of Shire PLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Shire PLC's stock price today?

One share of Shire PLC stock can currently be purchased for approximately $147.37.

How big of a company is Shire PLC?

Shire PLC has a market capitalization of $43.61 billion and generates $11.3966 billion in revenue each year. The biopharmaceutical company earns $327.4 million in net income (profit) each year or $5.31 on an earnings per share basis. Shire PLC employs 23,906 workers across the globe.

How can I contact Shire PLC?

Shire PLC's mailing address is Miesian Plaza 50-58 Baggot Street Lower, Block 2, DUBLIN, D02 HW68, Ireland. The biopharmaceutical company can be reached via phone at +353-1-6096000 or via email at [email protected]


MarketBeat Community Rating for Shire PLC (NASDAQ SHPG)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  828 (Vote Outperform)
Underperform Votes:  364 (Vote Underperform)
Total Votes:  1,192
MarketBeat's community ratings are surveys of what our community members think about Shire PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Shire PLC (NASDAQ:SHPG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 5 Hold Ratings, 10 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $212.18 (43.98% upside)
Consensus Price Target History for Shire PLC (NASDAQ:SHPG)
Price Target History for Shire PLC (NASDAQ:SHPG)
Analysts' Ratings History for Shire PLC (NASDAQ:SHPG)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/16/2017Royal Bank Of CanadaReiterated RatingBuyN/AView Rating Details
11/16/2017Cantor FitzgeraldSet Price TargetBuy$222.00N/AView Rating Details
11/14/2017Liberum CapitalUpgradeHold -> BuyN/AView Rating Details
10/30/2017FBR & CoReiterated RatingBuy$201.00N/AView Rating Details
10/29/2017Cowen and CompanySet Price TargetBuy$225.00N/AView Rating Details
10/27/2017Piper Jaffray CompaniesReiterated RatingHold$160.00N/AView Rating Details
10/8/2017Stifel NicolausReiterated RatingBuy$245.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$196.00MediumView Rating Details
8/11/2017Barclays PLCDowngradeOverweight -> Equal WeightLowView Rating Details
8/9/2017Jefferies Group LLCReiterated RatingHold$216.00 -> $206.00LowView Rating Details
7/17/2017BTIG ResearchReiterated RatingBuy$242.00LowView Rating Details
7/13/2017Sanford C. BernsteinReiterated RatingMarket Perform$210.00LowView Rating Details
4/17/2017Goldman Sachs Group, Inc. (The)Boost Price TargetOverweight$202.00 -> $214.00LowView Rating Details
2/17/2017GuggenheimReiterated RatingNeutralN/AView Rating Details
12/2/2016Societe GeneraleInitiated CoverageBuyN/AView Rating Details
11/14/2016Leerink SwannSet Price TargetBuy$198.00N/AView Rating Details
11/7/2016J P Morgan Chase & CoReiterated RatingOverweightN/AView Rating Details
11/3/2016Citigroup Inc.Reiterated RatingBuyN/AView Rating Details
11/2/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
10/23/2016BNP ParibasReiterated RatingBuyN/AView Rating Details
10/8/2016Shore CapitalReiterated RatingBuyN/AView Rating Details
6/3/2016Morgan StanleyReiterated RatingOverweightN/AView Rating Details
5/23/2016Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
3/30/2016Bank of America CorporationReiterated RatingBuyN/AView Rating Details
2/13/2016Northland SecuritiesReiterated RatingBuyN/AView Rating Details
2/8/2016Susquehanna Bancshares IncLower Price TargetPositive$280.00 -> $220.00N/AView Rating Details
1/18/2016Credit Suisse GroupUpgradeBuyN/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Shire PLC (NASDAQ:SHPG)
Earnings by Quarter for Shire PLC (NASDAQ:SHPG)
Earnings History by Quarter for Shire PLC (NASDAQ SHPG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/15/2018        
10/27/20179/30/2017$3.64$3.81$3.70 billionViewN/AView Earnings Details
8/3/20176/30/2017$3.53$3.73$3.75 billionViewListenView Earnings Details
5/2/2017Q1 17$3.22$3.63$3.57 billionViewListenView Earnings Details
2/16/2017Q416$3.24$3.37$3.78 billion$3.81 billionViewN/AView Earnings Details
11/1/2016Q316$3.21$3.17$3.57 billion$3.45 billionViewN/AView Earnings Details
8/2/2016Q216$3.03$3.38$2.28 billion$2.43 millionViewN/AView Earnings Details
4/29/2016Q1$3.05$3.19$1.71 billion$1.71 billionViewListenView Earnings Details
2/11/2016Q415$2.89$2.97$1.69 million$1.72 billionViewListenView Earnings Details
10/23/2015Q315$2.87$3.24$1.63 billion$1.58 billionViewListenView Earnings Details
7/23/2015Q215$2.81$2.63$1.59 billion$1.56 billionViewListenView Earnings Details
4/30/2015Q115$2.56$2.84$1.47 billion$1.49 billionViewN/AView Earnings Details
2/12/2015Q115$2.68$2.63$1.53 billion$1.58 billionViewN/AView Earnings Details
10/24/2014Q314$2.47$2.93$1.46 billion$1.55 billionViewListenView Earnings Details
7/18/2014Q214$2.45$2.67$1.45 billion$1.50 billionViewN/AView Earnings Details
5/1/2014Q114$2.22$2.36$1.38 billion$1.35 billionViewN/AView Earnings Details
2/13/2014Q413$2.02$2.26$1.28 billion$1.33 billionViewN/AView Earnings Details
10/24/2013Q213$1.65$1.77$1.23 billion$1.24 billionViewN/AView Earnings Details
7/25/2013$1.60$1.79$1.21 billion$1.28 billionViewN/AView Earnings Details
5/2/2013Q113$1.56$1.63$1.21 billion$1.16 billionViewN/AView Earnings Details
2/14/2013Q412$1.58$1.58$1.20 billion$1.20 billionViewN/AView Earnings Details
10/25/2012$1.47$1.36ViewN/AView Earnings Details
8/1/2012$1.52$1.68ViewN/AView Earnings Details
4/26/2012$0.52$1.24ViewN/AView Earnings Details
2/9/2012$0.48$0.44ViewN/AView Earnings Details
10/28/2011$1.31$1.28ViewN/AView Earnings Details
7/28/2011$1.24$1.33ViewN/AView Earnings Details
4/28/2011$1.18$1.23ViewN/AView Earnings Details
2/10/2011$1.04$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Shire PLC (NASDAQ:SHPG)
2017 EPS Consensus Estimate: $14.66
2018 EPS Consensus Estimate: $16.52
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$3.22$3.36$3.31
Q2 20174$3.53$3.69$3.61
Q3 20175$3.59$3.89$3.74
Q4 20175$3.72$4.26$3.99
Q1 20182$3.97$4.01$3.99
Q2 20182$3.97$4.13$4.05
Q3 20182$4.07$4.08$4.08
Q4 20182$4.37$4.43$4.40
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Shire PLC (NASDAQ:SHPG)
Most Recent Dividend:10/20/2017
Annual Dividend:$0.92
Dividend Yield:0.62%
Payout Ratio:17.33% (Trailing 12 Months of Earnings)
6.13% (Based on This Year's Estimates)
5.74% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Shire PLC (NASDAQ:SHPG)

Dividend History by Quarter for Shire PLC (NASDAQ SHPG)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/11/2017semiannual$0.150.21%9/7/20179/8/201710/20/2017
2/24/2017$0.773/8/20173/10/20174/25/2017
8/5/2016$0.149/7/20169/9/201610/7/2016
2/11/2016$0.673/9/20163/11/20164/12/2016
7/23/2015$0.139/2/20159/4/201510/2/2015
2/23/2015semiannual$0.570.48%3/11/20153/13/20154/14/2015
8/4/2014semiannual$0.110.09%9/3/20149/5/201410/3/2014
2/20/2014semiannual$0.510.61%3/5/20143/7/20144/8/2014
7/29/2013semiannual$0.090.16%9/4/20139/6/201310/3/2013
2/19/2013semiannual$0.440.92%3/6/20133/8/20134/9/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Shire PLC (NASDAQ SHPG)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Shire PLC (NASDAQ:SHPG)
Latest Headlines for Shire PLC (NASDAQ SHPG)
Source:
DateHeadline
Ultragenyxs rhGUS Gets FDA Nod for Rare Genetic DiseaseUltragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease
www.nasdaq.com - November 17 at 7:06 PM
Cantor Fitzgerald Reiterates "$222.00" Price Target for Shire PLC (SHPG)Cantor Fitzgerald Reiterates "$222.00" Price Target for Shire PLC (SHPG)
www.americanbankingnews.com - November 16 at 3:28 PM
Shire PLC (SHPG) Stock Rating Reaffirmed by Royal Bank Of CanadaShire PLC (SHPG) Stock Rating Reaffirmed by Royal Bank Of Canada
www.americanbankingnews.com - November 16 at 3:28 PM
Polygon Management Ltd. Buys Shire PLC, IAC/InterActiveCorp, Ambac Financial Group Inc, Sells ... - NasdaqPolygon Management Ltd. Buys Shire PLC, IAC/InterActiveCorp, Ambac Financial Group Inc, Sells ... - Nasdaq
www.nasdaq.com - November 15 at 3:42 PM
Shire PLC (SHPG) Lifted to Buy at Liberum CapitalShire PLC (SHPG) Lifted to Buy at Liberum Capital
www.americanbankingnews.com - November 14 at 8:28 PM
Shire: CHMP Recommends Hemophilia A Drug ADYNOVI For EU Marketing AuthorizationShire: CHMP Recommends Hemophilia A Drug ADYNOVI For EU Marketing Authorization
www.nasdaq.com - November 14 at 7:53 AM
European advisory group backs Shires long-acting Factor VIII for hemophilia AEuropean advisory group backs Shire's long-acting Factor VIII for hemophilia A
seekingalpha.com - November 14 at 7:53 AM
CHMP recommends EU marketing authorization for ADYNOVI®  for adults and adolescents with Hemophilia ACHMP recommends EU marketing authorization for ADYNOVI® for adults and adolescents with Hemophilia A
finance.yahoo.com - November 14 at 7:53 AM
Analytics for Industry Group Rank Make Shire (SHPG) a SellAnalytics for Industry Group Rank Make Shire (SHPG) a Sell
investorplace.com - November 13 at 4:58 PM
Dan Loeb Soars High in Alibaba - NasdaqDan Loeb Soars High in Alibaba - Nasdaq
www.nasdaq.com - November 11 at 1:34 PM
Shire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and OncologyShire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and Oncology
feeds.benzinga.com - November 10 at 7:56 AM
FY2019 EPS Estimates for Shire PLC (SHPG) Reduced by SunTrust BanksFY2019 EPS Estimates for Shire PLC (SHPG) Reduced by SunTrust Banks
www.americanbankingnews.com - November 9 at 3:40 PM
Shire PLC Forecasted to Post Q4 2017 Earnings of $3.80 Per Share (SHPG)Shire PLC Forecasted to Post Q4 2017 Earnings of $3.80 Per Share (SHPG)
www.americanbankingnews.com - November 8 at 1:14 PM
$4.00 Billion in Sales Expected for Shire PLC (SHPG) This Quarter$4.00 Billion in Sales Expected for Shire PLC (SHPG) This Quarter
www.americanbankingnews.com - November 5 at 6:44 AM
ETFs with exposure to Shire Plc : November 3, 2017ETFs with exposure to Shire Plc : November 3, 2017
finance.yahoo.com - November 4 at 2:50 PM
Zacks: Analysts Anticipate Shire PLC (SHPG) to Announce $3.90 EPSZacks: Analysts Anticipate Shire PLC (SHPG) to Announce $3.90 EPS
www.americanbankingnews.com - November 3 at 7:34 PM
Head-To-Head Comparison: Shire PLC (SHPG) vs. Impax Laboratories (IPXL)Head-To-Head Comparison: Shire PLC (SHPG) vs. Impax Laboratories (IPXL)
www.americanbankingnews.com - November 2 at 5:30 PM
Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plcXenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc
finance.yahoo.com - November 2 at 8:45 AM
Earnings Review and Free Research Report: Eli Lilly’s Adjusted EPS Increased 19%Earnings Review and Free Research Report: Eli Lilly’s Adjusted EPS Increased 19%
finance.yahoo.com - November 2 at 8:44 AM
Shire PLC (SHPG) Given Consensus Recommendation of "Buy" by BrokeragesShire PLC (SHPG) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 1 at 3:42 PM
Q4 2017 EPS Estimates for Shire PLC Cut by William Blair (SHPG)Q4 2017 EPS Estimates for Shire PLC Cut by William Blair (SHPG)
www.americanbankingnews.com - November 1 at 11:31 AM
FY2017 EPS Estimates for Shire PLC (SHPG) Cut by Cantor FitzgeraldFY2017 EPS Estimates for Shire PLC (SHPG) Cut by Cantor Fitzgerald
www.americanbankingnews.com - November 1 at 8:54 AM
Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong - NasdaqShire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong - Nasdaq
www.nasdaq.com - October 31 at 9:25 AM
Shire (SHPG) Q3 Earnings Beat, Immunology Franchise StrongShire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong
finance.yahoo.com - October 31 at 9:25 AM
Analysts Issue Forecasts for Shire PLCs FY2017 Earnings (SHPG)Analysts Issue Forecasts for Shire PLC's FY2017 Earnings (SHPG)
www.americanbankingnews.com - October 31 at 6:48 AM
Shire PLC to Post FY2017 Earnings of $15.10 Per Share, FBR & Co Forecasts (SHPG)Shire PLC to Post FY2017 Earnings of $15.10 Per Share, FBR & Co Forecasts (SHPG)
www.americanbankingnews.com - October 31 at 6:48 AM
Falling Earnings Visibility Keeps Shire (SHPG) a SellFalling Earnings Visibility Keeps Shire (SHPG) a Sell
investorplace.com - October 30 at 3:59 PM
Fund manager, analysts make the case for this ‘loathed’ pharma stockFund manager, analysts make the case for this ‘loathed’ pharma stock
finance.yahoo.com - October 30 at 7:05 AM
Shire PLC (SHPG) Stock Rating Reaffirmed by Cantor FitzgeraldShire PLC (SHPG) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - October 28 at 2:08 PM
Shire PLC (SHPG) Posts  Earnings Results, Beats Estimates By $0.15 EPSShire PLC (SHPG) Posts Earnings Results, Beats Estimates By $0.15 EPS
www.americanbankingnews.com - October 27 at 9:32 PM
Zacks Investment Research Upgrades Shire PLC (SHPG) to HoldZacks Investment Research Upgrades Shire PLC (SHPG) to Hold
www.americanbankingnews.com - October 27 at 1:00 PM
Shire PLC (SHPG) Releases FY17 Earnings GuidanceShire PLC (SHPG) Releases FY17 Earnings Guidance
www.americanbankingnews.com - October 27 at 8:56 AM
Shire plc : 3rd Quarter ResultsShire plc : 3rd Quarter Results
feeds.benzinga.com - October 27 at 8:05 AM
Shire Receives European Approval for Label Extension of FIRAZYR® (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Paediatric PatientsShire Receives European Approval for Label Extension of FIRAZYR® (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Paediatric Patients
feeds.benzinga.com - October 26 at 2:51 AM
Shire Gets Orphan Drug Designation For Gene Therapy Candidate SHP654 - NasdaqShire Gets Orphan Drug Designation For Gene Therapy Candidate SHP654 - Nasdaq
www.nasdaq.com - October 25 at 10:38 AM
Shire (SHPG) a Sell on Falling Quant Score - Investorplace.comShire (SHPG) a Sell on Falling Quant Score - Investorplace.com
investorplace.com - October 25 at 10:38 AM
Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment of Hemophilia AShire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment of Hemophilia A
feeds.benzinga.com - October 25 at 8:04 AM
Shire to Present New Data to Help Advance Understanding of Rare DiseasesShire to Present New Data to Help Advance Understanding of Rare Diseases
www.nasdaq.com - October 24 at 9:57 AM
ETFs with exposure to Shire Plc : October 23, 2017ETFs with exposure to Shire Plc : October 23, 2017
finance.yahoo.com - October 24 at 9:57 AM
Shire PLC Expected to Post Q3 2017 Earnings of $3.70 Per Share (SHPG)Shire PLC Expected to Post Q3 2017 Earnings of $3.70 Per Share (SHPG)
www.americanbankingnews.com - October 23 at 1:30 AM
Shire PLC (SHPG) Earns Buy Rating from Analysts at FBR & CoShire PLC (SHPG) Earns Buy Rating from Analysts at FBR & Co
www.americanbankingnews.com - October 22 at 5:16 PM
Financial Analysis: Shire PLC (SHPG) vs. Its CompetitorsFinancial Analysis: Shire PLC (SHPG) vs. Its Competitors
www.americanbankingnews.com - October 21 at 4:34 PM
Shire PLC (SHPG) Stock Rating Lowered by Zacks Investment ResearchShire PLC (SHPG) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - October 20 at 12:32 PM
Create the Soundtrack to Your Unique Day with "Compose Your Life"Create the Soundtrack to Your Unique Day with "Compose Your Life"
finance.yahoo.com - October 20 at 8:05 AM
William Blair Analysts Boost Earnings Estimates for Shire PLC (SHPG)William Blair Analysts Boost Earnings Estimates for Shire PLC (SHPG)
www.americanbankingnews.com - October 19 at 11:28 AM
Generic Restasis Risk Metastasizes To Shire - Seeking AlphaGeneric Restasis Risk Metastasizes To Shire - Seeking Alpha
seekingalpha.com - October 19 at 8:48 AM
Q3 2017 EPS Estimates for Shire PLC (SHPG) Lifted by SunTrust BanksQ3 2017 EPS Estimates for Shire PLC (SHPG) Lifted by SunTrust Banks
www.americanbankingnews.com - October 19 at 7:18 AM
Shire PLC to Post FY2019 Earnings of $18.17 Per Share, William Blair Forecasts (SHPG)Shire PLC to Post FY2019 Earnings of $18.17 Per Share, William Blair Forecasts (SHPG)
www.americanbankingnews.com - October 18 at 2:40 PM
Analysts Issue Forecasts for Shire PLCs FY2018 Earnings (SHPG)Analysts Issue Forecasts for Shire PLC's FY2018 Earnings (SHPG)
www.americanbankingnews.com - October 18 at 1:10 PM
Why Shire plc (LSE:SHP) Delivered An Inferior ROE Compared To The IndustryWhy Shire plc (LSE:SHP) Delivered An Inferior ROE Compared To The Industry
finance.yahoo.com - October 18 at 8:30 AM

Social Media

Financials

Financials are not available for this stock.

Chart

Shire PLC (NASDAQ SHPG) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.